Moberg Pharma Obtains US Patent for Fungal Nail Infection Dosing Regimen

MT Newswires · 11/03 04:22
04:22 AM EST, 11/03/2026 (MT Newswires) -- Moberg Pharma (MOB.ST) secured a new patent in the US for an improved dosing regimen for MOB-015, a topical drug for onychomycosis or fungal nail infection. The patent from the US Patent and Trademark Office is projected to expire in December 2041, according to a Tuesday release. Patent applications in other markets are pending. The Swedish pharmaceutical company aims to run an additional phase 3 study to support a future approval from the US Food and Drug Administration.